MedTrace Logo

Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty

NCT00306228 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2009-09-28

No results posted yet for this study

Summary

The conceptual hypothesis of this study is that, in patients with acute myocardial infarction and ST-segment elevation, the strategy of performing coronary angioplasty of the culprit artery with paclitaxel eluting stent significantly reduces the rate of restenosis in comparison with bare stents.

The conceptual hypothesis of this study is that, in patients with acute myocardial infarction and ST-segment elevation, the strategy of performing coronary stent-angioplasty of the culprit artery under the protection of tirofiban 120 minutes after fibrinolytic significantly improves epicardial and myocardial infusion in comparison with the strategy of performing immediate intravenous thrombolysis (tenecteplase plus enoxaparine) followed by coronary angiography and adequate revascularization.

Conditions

Interventions

PROCEDURE

Postfibrinolysis percutaneous coronary intervention

implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis

PROCEDURE

Postfibrinolysis percutaneous coronary intervention

implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis

PROCEDURE

Postfibrinolysis percutaneous coronary intervention

implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis

PROCEDURE

Postfibrinolysis percutaneous coronary intervention

implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis

Sponsors & Collaborators

  • Spanish Ministry of Health.

    collaborator UNKNOWN

  • Ministry of Science and Innovation, Spain

    collaborator OTHER_GOV

  • GRACIA Group

    lead OTHER

Principal Investigators

  • Francisco Fernandez-Aviles, MD, PhD · ICICOR, Hospital Clínico Universitario Valladolid, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2008-01-31
Completion
2009-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306228 on ClinicalTrials.gov